Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity
Jin Hee Shin,1 Kishore M Gadde2 1Department of Community and Family Medicine, Duke University Medical Center, 2Obesity Clinical Trials Program, Duke University Medical Center, Durham, NC, USA Abstract: Qsymia™ (Vivus Inc, Mountain View, CA, USA), a combination of phentermine and delayed-re...
Guardado en:
Autores principales: | Shin JH, Gadde KM |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8e7b8c78bbcb44519fdfc944b618afb1 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Management of obesity and cardiometabolic risk – role of phentermine/extended release topiramate
por: Sweeting AN, et al.
Publicado: (2014) -
Effects of Orlistat/Phentermine versus Phentermine on Vascular Endothelial Cell Function in Obese and Overweight Adults: A Randomized, Double-Blinded, Placebo-Controlled Trial
por: Kwon YJ, et al.
Publicado: (2021) -
Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
por: Karen Barnard, et al.
Publicado: (2010) -
Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes
por: Maffioli P, et al.
Publicado: (2011) -
The clinical utility of aflibercept for diabetic macular edema
por: Stewart MW
Publicado: (2015)